Should I buy or sell MorphoSys stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares. View MOR analyst ratings or view top-rated stocks .

What is MorphoSys' stock price target for 2024?

8 brokers have issued 1 year price targets for MorphoSys' shares. Their MOR share price targets range from $4.75 to $18.25. On average, they anticipate the company's stock price to reach $11.78 in the next twelve months. This suggests that the stock has a possible downside of 34.5%. View analysts price targets for MOR or view top-rated stocks among Wall Street analysts .

How have MOR shares performed in 2024?

MorphoSys' stock was trading at $9.90 at the beginning of the year. Since then, MOR stock has increased by 81.7% and is now trading at $17.99. View the best growth stocks for 2024 here .

Are investors shorting MorphoSys?

MorphoSys saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,630,000 shares, a drop of 22.0% from the March 15th total of 2,090,000 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is currently 0.8 days. View MorphoSys' Short Interest .

When is MorphoSys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our MOR earnings forecast .

How were MorphoSys' earnings last quarter?

MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings results on Wednesday, March, 13th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $1.25. The firm had revenue of $63.53 million for the quarter, compared to analysts' expectations of $76.30 million. MorphoSys had a negative net margin of 80.07% and a negative trailing twelve-month return on equity of 694.31%.

What ETF holds MorphoSys' stock?

Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio.

What is Simon E. Moroney's approval rating as MorphoSys' CEO?

5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com . Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did MorphoSys IPO?

MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

How do I buy shares of MorphoSys?

Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MOR

MorphoSys (MOR) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free MOR Stock Alerts

$17.99

-0.03 (-0.17%)

(As of 02:10 PM ET)

Compare

Today's Range: $17.93
▼
$18.02
50-Day Range: $16.27
▼
$18.18
52-Week Range: $4.18
▼
$18.31

Volume: 322,038 shs
Average Volume: 1.83 million shs
Market Capitalization: $2.71 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.78

Get MorphoSys alerts:

MorphoSys MarketRank™ Stock Analysis

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 34.5% Downside
$11.78 Price Target
Short Interest: Healthy
1.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.74
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.08) to ($0.89) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.57 out of 5 stars

Medical Sector

881st out of 930 stocks

Pharmaceutical Preparations Industry

408th out of 430 stocks

1.2

Analyst's Opinion

Consensus Rating
MorphoSys has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.
Amount of Analyst Coverage
MorphoSys has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.08% of the outstanding shares of MorphoSys have been sold short.
Short Interest Ratio / Days to Cover
MorphoSys has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MorphoSys has recently decreased by 22.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MorphoSys does not currently pay a dividend.
Dividend Growth
MorphoSys does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MOR.

2.6

News and Social Media Coverage

News Sentiment
MorphoSys has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for MorphoSys this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for MOR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added MorphoSys to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MorphoSys insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.05% of the stock of MorphoSys is held by insiders.
Percentage Held by Institutions
Only 18.38% of the stock of MorphoSys is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MorphoSys are expected to grow in the coming year, from ($2.08) to ($0.89) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MorphoSys is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MorphoSys is -11.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MorphoSys has a P/B Ratio of 51.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About MorphoSys Stock (NASDAQ:MOR)

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

MOR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MOR Stock News Headlines

April 11, 2024 | markets.businessinsider.com

EQS-News: MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024 | markets.businessinsider.com

MorphoSys Recommends Shareholders Accept Offer By Novartis - Quick Facts

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

April 11, 2024 | finance.yahoo.com

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024 | businesswire.com

MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

April 11, 2024 | finanznachrichten.de

Aspermont Limited: Aspermont is Announcing 'Future of Mining Perth': Unveiling Innovations, Sustainability, and Industry Growth!

April 11, 2024 | reuters.com

Novartis begins tender offer for MorphoSys

April 11, 2024 | globenewswire.com

Novartis tender offer for MorphoSys AG commences

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 20, 2024 | investing.com

MorphoSys AG ADR (MOR)

March 16, 2024 | seekingalpha.com

MorphoSys AG (MOR) Q4 2023 Earnings Call Transcript

March 16, 2024 | uk.investing.com

Earnings call: MorphoSys reported a strong performance for 2023

March 16, 2024 | ca.finance.yahoo.com

NVS Apr 2024 80.000 call

March 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement Prospects

March 14, 2024 | msn.com

Biotech Rally Gets $100 Billion M&A Lift With More Deals to Come

March 13, 2024 | businesswire.com

MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

March 13, 2024 | finance.yahoo.com

EltaMD Establishes March 13th as National Dermatologist Day, Building a Healthier Future for All

March 12, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Morphosys's earnings

March 12, 2024 | markets.businessinsider.com

Here's what Wall Street expects from MorphoSys's earnings report

March 12, 2024 | reuters.com

German competition regulator clears path for Novartis takeover of MorphoSys

March 11, 2024 | finance.yahoo.com

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

February 6, 2024 | benzinga.com

Decoding MorphoSys's Options Activity: What's the Big Picture?

February 6, 2024 | morningstar.com

MorphoSys Shares Jump After It Agrees to $2.9 Billion Takeover by Novartis

February 6, 2024 | marketwatch.com

MorphoSys Shares Jump After It Agrees to $2.9 Bln Takeover by Novartis

February 6, 2024 | msn.com

MorphoSys drops amid speculation Novartis could walk from deal

February 6, 2024 | finance.yahoo.com

Novartis Buys MorphoSys for €2.7 Billion to Get Cancer Drugs

February 5, 2024 | msn.com

Novartis to bolster its oncology portfolio with acquisition of MorphoSys

See More Headlines

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MOR
CUSIP: N/A
CIK: 1340243
Web: www.morphosys.com
Phone: (498) 989-9270
Fax: 49-89-8992-7222
Employees: 524
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.78
High Stock Price Target: $18.25
Low Stock Price Target: $4.75
Potential Upside/Downside: -34.5%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.56)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-205,350,000.00
Net Margins: -80.07%
Pretax Margin: -80.13%
Return on Equity: -694.31%
Return on Assets: -8.96%

Debt

Debt-to-Equity Ratio: 4.98
Current Ratio: 3.08
Quick Ratio: 2.84

Sales & Book Value

Annual Sales: $257.89 million
Price / Sales: 10.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.35 per share
Price / Book: 51.40

Miscellaneous

Outstanding Shares: 150,620,000
Free Float: 150,546,000
Market Cap: $2.71 billion
Optionable: Not Optionable
Beta: 1.17

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jean-Paul Kress M.D. (Age 59)
Chairman of Management Board, MD & CEO
Comp: $1.91M
Dr. Lucinda Crabtree Ph.D. (Age 45)
CFO & Member of Management Board
Comp: $764.53k
Ms. Charlotte Lohmann (Age 54)
Chief Legal and Human Resources Officer & Member of Management Board
Comp: $513.54k
Mr. Klaus De Wall
Head of Accounting & Tax
Dr. Margit Urban
Head of Discovery Alliances & Technologies
Dr. Julia Neugebauer Ph.D.
Head of Investor Relations
Dr. Barbara Krebs-Pohl Ph.D.
Chief Business Officer
Dr. Günter Wellnhofer
Head of Technical Operations
Dr. Harald Watzka
Head of Alliance Management
Ms. Yen Ching Chua
Head of Clinical Operations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MOR Stock Analysis - Frequently Asked Questions

Should I buy or sell MorphoSys stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOR, but not buy additional shares or sell existing shares.
View MOR analyst ratings or view top-rated stocks.
What is MorphoSys' stock price target for 2024?: 8 brokers have issued 1 year price targets for MorphoSys' shares. Their MOR share price targets range from $4.75 to $18.25. On average, they anticipate the company's stock price to reach $11.78 in the next twelve months. This suggests that the stock has a possible downside of 34.5%.
View analysts price targets for MOR or view top-rated stocks among Wall Street analysts.
How have MOR shares performed in 2024?: MorphoSys' stock was trading at $9.90 at the beginning of the year. Since then, MOR stock has increased by 81.7% and is now trading at $17.99.
View the best growth stocks for 2024 here.
Are investors shorting MorphoSys?: MorphoSys saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,630,000 shares, a drop of 22.0% from the March 15th total of 2,090,000 shares. Based on an average trading volume of 2,010,000 shares, the short-interest ratio is currently 0.8 days.
View MorphoSys' Short Interest.
When is MorphoSys' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our MOR earnings forecast.
How were MorphoSys' earnings last quarter?: MorphoSys AG (NASDAQ:MOR) issued its quarterly earnings results on Wednesday, March, 13th. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $1.25. The firm had revenue of $63.53 million for the quarter, compared to analysts' expectations of $76.30 million. MorphoSys had a negative net margin of 80.07% and a negative trailing twelve-month return on equity of 694.31%.

What ETF holds MorphoSys' stock?: Range Cancer Therapeutics ETF holds 17,145 shares of MOR stock, representing 1.32% of its portfolio.
What is Simon E. Moroney's approval rating as MorphoSys' CEO?: 5 employees have rated MorphoSys Chief Executive Officer Simon E. Moroney on Glassdoor.com. Simon E. Moroney has an approval rating of 100% among the company's employees. This puts Simon E. Moroney in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
When did MorphoSys IPO?: MorphoSys (MOR) raised $200 million in an initial public offering on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.
How do I buy shares of MorphoSys?: Shares of MOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MOR) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MorphoSys (MOR) Stock Price, News & Analysis

MorphoSys MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MorphoSys Stock (NASDAQ:MOR)

MOR Stock Price History

MOR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

MOR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™